New targets for NAFLDKey points

Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our un...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lucia Parlati, Marion Régnier, Hervé Guillou, Catherine Postic
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
FXR
LXR
Acceso en línea:https://doaj.org/article/9d4fca391fdc4664876e3b618ff56737
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Summary: Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets.